Calquence® (acalabrutinib) – New formulation approval
August 5, 2022 - AstraZeneca announced the FDA approval of AstraZeneca’s Calquence (acalabrutinib) tablet, for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy, and for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Top